Colorectal Cancer Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026

Published: Mar 2022

Pages: 138

SKU: IRTNTR72411

Snapshot

The colorectal cancer therapeutics market share is expected to increase to USD 2.45 bn from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.43%.

This colorectal cancer therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers colorectal cancer therapeutics market segmentation by type (targeted therapy, immunotherapy, and chemotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).

What will the Colorectal Cancer Therapeutics Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Colorectal Cancer Therapeutics Market Size for the Forecast Period and Other Important Statistics

The colorectal cancer therapeutics market report also offers information on several market vendors, including Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol-Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.

Parent Market Analysis

Technavio categorizes the global colorectal cancer therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the colorectal cancer therapeutics market during the forecast period.

Who are the Major Colorectal Cancer Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

This statistical study of the colorectal cancer therapeutics market encompasses successful business strategies deployed by the key vendors. The colorectal cancer therapeutics market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.

Product Insights and News

Amgen Inc. - The company offers colorectal cancer therapeutics such as Vectibix.
Amgen Inc. - Under the unified business segment, the company offers human therapeutics.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The colorectal cancer therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Colorectal Cancer Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the colorectal cancer therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Colorectal Cancer Therapeutics Market: Key Drivers, Trends, and Challenges

The increasing geriatric population is notably driving the colorectal cancer therapeutics market growth, although factors such as patent expiration of novel therapeutics may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the colorectal cancer therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Colorectal Cancer Therapeutics Market Driver

One of the key factors driving the global colorectal cancer therapeutics market growth is the increasing geriatric population. According to the CDC, more than 90% of colorectal cancer cases occur in people in the age group of 50 years and above. As per the data collected by the World Bank and National Institutes of Health (NIH), the percentage of the geriatric population is expected to grow from 9.3% in 2020 to approximately 17% by 2050 globally. In addition, according to the US Census Bureau, the population aged 65 years and above this is expected to rise to 1,566 million by 2050. Hence, the increase in the number of colorectal cancer cases among the growing geriatric population is expected to increase and impel the growth of the market in focus during the forecast period.

Key Colorectal Cancer Therapeutics Market Trend

Development of small molecule kinase inhibitors is one of the key colorectal cancer therapeutics market trends that is expected to impact the industry positively in the forecast period. Several pharmaceutical companies are focusing on the development of safe, low-cost, and easy to administer small molecule drugs. Kinase inhibitors halt the protein phosphorylation process in cancer cells by blocking protein kinases. Regorafenib is the only kinase inhibitor available for the treatment of colorectal cancer. Hence, various pharmaceutical companies are developing kinase inhibitors for the treatment of colorectal cancer. For instance, F. Hoffmann-La Roche Ltd is conducting Phase II clinical trials on Entrectinib, a kinase inhibitor for the treatment of colorectal cancer. Such factors are expected to further support the market growth in the coming years.

Key Colorectal Cancer Therapeutics Market Challenge

One of the key challenges to the global colorectal cancer therapeutics market growth is the patent expiration of novel therapeutics. According to the World Trade Organization's TRIPS agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights), innovators can get a term of 20 years of exclusive patent rights on their novel pharmaceutical therapeutics from the date of application filing in the US and Europe. As a result, pharmaceutical companies sell their innovator products, especially biologics, at a high price until their patent expiration. However, the loss of patents of biologics can open opportunities for biosimilars for entry in the market, thereby increasing competition, which decreases the price of the original biologic therapeutics. Thus, the expiration of patents and other intellectual property rights of therapeutics such as AVASTIN (bevacizumab), VECTIBIX (panitumumab), and ZALTRAP (ziv-Aflibercept) is expected to hamper the growth of the market during the forecast period.

This colorectal cancer therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Which are the Key Regions for Colorectal Cancer Therapeutics Market?

For more insights on the market share of various regions Request for a FREE sample now!

36% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for colorectal cancer therapeutics in North America. Market growth in this region will be faster than the growth of the market in ROW.

The increase in demand for colorectal cancer therapeutics due to the high incidence of colorectal cancer will facilitate the colorectal cancer therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Type Segments in the Colorectal Cancer Therapeutics Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The colorectal cancer therapeutics market share growth by the targeted therapy segment will be significant during the forecast period. The expected marketing approvals of targeted biologics are also expected to drive the growth of the segment further in the coming years.

Donafenib is in Phase III stage of development by Suzhou Zelgen Biopharmaceuticals Co., Ltd. for the treatment of colorectal cancer and is expected to enter the market during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the colorectal cancer therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in:

Breast Cancer Therapeutics market - The market share is expected to increase by USD 13.85 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.95%.

Gynecological Cancers Therapeutics market - The market size is predicted to surge to USD 14.22 billion from 2021 to 2026 at a CAGR of 14.67%.

Oral Cancer Therapeutics market - The market share is expected to increase by USD 1.14 billion from 2021 to 2026, and the market's growth momentum will decelerate at a CAGR of 7.5%.

Throat Cancer Therapeutics market - The market size is predicted to surge to USD 1.82 billion from 2021 to 2026 at a CAGR of 6.7%.

Lung Cancer Therapeutics market - The market share has the potential to grow by USD 6.79 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.47%.

Colorectal Cancer Therapeutics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 5.43%
Market growth 2022-2026	$ 2.45 billion
Market structure	Fragmented
YoY growth (%)	4.15
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 36%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol-Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Colorectal Cancer Therapeutics Market Report?

CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will drive colorectal cancer therapeutics market growth during the next five years
Precise estimation of the colorectal cancer therapeutics market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the colorectal cancer therapeutics industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of colorectal cancer therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 06: Executive Summary – Chart on Incremental Growth
- Exhibit 07: Executive Summary – Data Table on Incremental Growth
- Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 09: Parent market
- Exhibit 10: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 11: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 12: Market segments

3.3 Market size 2021

3.4 Market outlook: Forecast for 2021-2026
- Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
- Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
- Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

4.1 Five forces summary
- Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

4.2 Bargaining power of buyers
- Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026

4.3 Bargaining power of suppliers
- Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

4.4 Threat of new entrants
- Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

4.5 Threat of substitutes
- Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

4.6 Threat of rivalry
- Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

4.7 Market condition
- Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

5.1 Market segments
- Exhibit 24: Chart on Type - Market share 2021-2026 (%)
- Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

5.2 Comparison by Type
- Exhibit 26: Chart on Comparison by Type
- Exhibit 27: Data Table on Comparison by Type

5.3 Targeted therapy - Market size and forecast 2021-2026
- Exhibit 28: Chart on Targeted therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 29: Data Table on Targeted therapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 30: Chart on Targeted therapy - Year-over-year growth 2021-2026 (%)
- Exhibit 31: Data Table on Targeted therapy - Year-over-year growth 2021-2026 (%)

5.4 Immunotherapy - Market size and forecast 2021-2026
- Exhibit 32: Chart on Immunotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 33: Data Table on Immunotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 34: Chart on Immunotherapy - Year-over-year growth 2021-2026 (%)
- Exhibit 35: Data Table on Immunotherapy - Year-over-year growth 2021-2026 (%)

5.5 Chemotherapy - Market size and forecast 2021-2026
- Exhibit 36: Chart on Chemotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 37: Data Table on Chemotherapy - Market size and forecast 2021-2026 ($ million)
- Exhibit 38: Chart on Chemotherapy - Year-over-year growth 2021-2026 (%)
- Exhibit 39: Data Table on Chemotherapy - Year-over-year growth 2021-2026 (%)

5.6 Market opportunity by Type
- Exhibit 40: Market opportunity by Type ($ million)

6 Customer Landscape

6.1 Customer landscape overview
- Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

7.1 Geographic segmentation
- Exhibit 42: Chart on Market share by geography 2021-2026 (%)
- Exhibit 43: Data Table on Market share by geography 2021-2026 (%)

7.2 Geographic comparison
- Exhibit 44: Chart on Geographic comparison
- Exhibit 45: Data Table on Geographic comparison

7.3 North America - Market size and forecast 2021-2026
- Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
- Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
- Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)

7.4 Europe - Market size and forecast 2021-2026
- Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
- Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
- Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)

7.5 Asia - Market size and forecast 2021-2026
- Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
- Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
- Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)

7.6 Rest of World (ROW) - Market size and forecast 2021-2026
- Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
- Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
- Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

7.7 US - Market size and forecast 2021-2026
- Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
- Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
- Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)

7.8 Germany - Market size and forecast 2021-2026
- Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
- Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
- Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)

7.9 UK - Market size and forecast 2021-2026
- Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
- Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
- Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

7.10 Canada - Market size and forecast 2021-2026
- Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
- Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
- Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)

7.11 China - Market size and forecast 2021-2026
- Exhibit 78: Chart on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 79: Data Table on China - Market size and forecast 2021-2026 ($ million)
- Exhibit 80: Chart on China - Year-over-year growth 2021-2026 (%)
- Exhibit 81: Data Table on China - Year-over-year growth 2021-2026 (%)

7.12 Market opportunity by geography
- Exhibit 82: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

8.3 Impact of drivers and challenges
- Exhibit 83: Impact of drivers and challenges in 2021 and 2026

8.4 Market trends

9 Vendor Landscape

9.1 Overview

9.2 Vendor landscape
- Exhibit 84: Overview on Criticality of inputs and Factors of differentiation

9.3 Landscape disruption
- Exhibit 85: Overview on factors of disruption

9.4 Industry risks
- Exhibit 86: Impact of key risks on business

10 Vendor Analysis

10.1 Vendors covered
- Exhibit 87: Vendors covered

10.2 Market positioning of vendors
- Exhibit 88: Matrix on vendor position and classification

10.3 Amgen Inc.
- Exhibit 89: Amgen Inc. - Overview
- Exhibit 90: Amgen Inc. - Business segments
- Exhibit 91: Amgen Inc. - Key offerings
- Exhibit 92: Amgen Inc. - Segment focus

10.4 Bayer AG
- Exhibit 93: Bayer AG - Overview
- Exhibit 94: Bayer AG - Business segments
- Exhibit 95: Bayer AG - Key news
- Exhibit 96: Bayer AG - Key offerings
- Exhibit 97: Bayer AG - Segment focus

10.5 Biocon Ltd.
- Exhibit 98: Biocon Ltd. - Overview
- Exhibit 99: Biocon Ltd. - Business segments
- Exhibit 100: Biocon Ltd. - Key offerings
- Exhibit 101: Biocon Ltd. - Segment focus

10.6 Bristol-Myers Squibb Co.
- Exhibit 102: Bristol-Myers Squibb Co. - Overview
- Exhibit 103: Bristol-Myers Squibb Co. - Product / Service
- Exhibit 104: Bristol-Myers Squibb Co. - Key offerings

10.7 Eli Lilly and Co.
- Exhibit 105: Eli Lilly and Co. - Overview
- Exhibit 106: Eli Lilly and Co. - Business segments
- Exhibit 107: Eli Lilly and Co. - Key offerings
- Exhibit 108: Eli Lilly and Co. - Segment focus

10.8 F. Hoffmann La Roche Ltd.
- Exhibit 109: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 110: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 111: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 112: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 113: F. Hoffmann La Roche Ltd. - Segment focus

10.9 Fresenius SE and Co. KGaA
- Exhibit 114: Fresenius SE and Co. KGaA - Overview
- Exhibit 115: Fresenius SE and Co. KGaA - Business segments
- Exhibit 116: Fresenius SE and Co. KGaA - Key offerings
- Exhibit 117: Fresenius SE and Co. KGaA - Segment focus

10.10 Merck and Co. Inc.
- Exhibit 118: Merck and Co. Inc. - Overview
- Exhibit 119: Merck and Co. Inc. - Business segments
- Exhibit 120: Merck and Co. Inc. - Key news
- Exhibit 121: Merck and Co. Inc. - Key offerings
- Exhibit 122: Merck and Co. Inc. - Segment focus

10.11 Sanofi SA
- Exhibit 123: Sanofi SA - Overview
- Exhibit 124: Sanofi SA - Business segments
- Exhibit 125: Sanofi SA - Key news
- Exhibit 126: Sanofi SA - Key offerings
- Exhibit 127: Sanofi SA - Segment focus

10.12 Viatris Inc.
- Exhibit 128: Viatris Inc. - Overview
- Exhibit 129: Viatris Inc. - Business segments
- Exhibit 130: Viatris Inc. - Key offerings
- Exhibit 131: Viatris Inc. - Segment focus

11 Appendix

11.1 Scope of the report

11.2 Inclusions and exclusions checklist
- Exhibit 132: Inclusions checklist
- Exhibit 133: Exclusions checklist

11.3 Currency conversion rates for US$
- Exhibit 134: Currency conversion rates for US$

11.4 Research methodology
- Exhibit 135: Research methodology
- Exhibit 136: Validation techniques employed for market sizing
- Exhibit 137: Information sources

11.5 List of abbreviations
- Exhibit 138: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

colorectal cancer therapeutics market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis